Comparison between Fractal Industries IPO and Goldline Pharmaceutical IPO.
Fractal Industries IPO is a SME Bookbuilding IPO proposed to list at BSE SME while Goldline Pharmaceutical IPO is a SME Bookbuilding proposed to list at BSE SME.
| Fractal Industries IPO | Goldline Pharmaceutical IPO | |
|---|---|---|
| Logo |  |  |
| Issue Category | SME | SME |
| Issue Type | IPO | IPO |
| Process Type | Bookbuilding | Bookbuilding |
| Listing At | BSE SME | BSE SME |
| Lead Managers | Finaax Capital Advisors Pvt.Ltd. | Cumulative Capital Pvt.Ltd. |
| Registrar | Kfin Technologies Ltd. | Bigshare Services Pvt.Ltd. |
| Market Maker | Shreni Shares Ltd. | |
| DRHP | DRHP  | DRHP |
| RHP | RHP | |
| Final Prospectus | Final Prospectus | |
| Anchor Investor | Anchor Investor | |
| IPO Allotment URL | IPO Allotment URL |
The total issue size of Fractal Industries IPO is up to ₹46.54 Cr whereas the issue size of the Goldline Pharmaceutical IPO is up to ₹0.00 Cr. The final issue price of Fractal Industries IPO is ₹216.00 per share and of Goldline Pharmaceutical IPO is .
| Fractal Industries IPO | Goldline Pharmaceutical IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ₹205.00 per share | |
| Issue Price (Upper) | ₹216.00 per share | |
| Issue Price (Final) | ₹216.00 per share | |
| Discount (Retail) | ||
| Discount (Employee) | ||
| Market Lot Size | 600 shares | |
| Fresh Issue Size | 21,54,600 shares | 30,00,000 shares |
| Fresh Issue Size (Amount) | up to ₹46.54 Cr | up to ₹0.00 Cr |
| OFS Issue Size | 0 shares | 0 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
| Issue Size Total | 21,54,600 shares | 30,00,000 shares |
| Issue Size Total (Amount) | up to ₹46.54 Cr | up to ₹0.00 Cr |
Fractal Industries IPO opens on Feb 16, 2026, while Goldline Pharmaceutical IPO opens on . The closing date of Fractal Industries IPO and Goldline Pharmaceutical IPO is Feb 18, 2026, and , respectively.
| Fractal Industries IPO | Goldline Pharmaceutical IPO | |
|---|---|---|
| Anchor Bid Date | Feb 13, 2026 | |
| Issue Open | Feb 16, 2026 | |
| Issue Close | Feb 18, 2026 | |
| Basis Of Allotment (Tentative) | Feb 20, 2026 | |
| Initiation of Refunds (Tentative) | Feb 23, 2026 | |
| Credit of Share (Tentative) | Feb 23, 2026 | |
| Listing date (Tentative) | Feb 24, 2026 | |
| Anchor Lockin End date 1 | Mar 22, 2026 | |
| Anchor Lockin End date 2 | May 21, 2026 |
Fractal Industries IPO P/E ratio is 15.99, as compared to Goldline Pharmaceutical IPO P/E ratio of .
| Fractal Industries IPO | Goldline Pharmaceutical IPO | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated Consolidated)
| Company Financials (Restated)Goldline Pharmaceutical Ltd.'s revenue increased by 19% and profit after tax (PAT) rose by 57% between the financial year ending with March 31, 2025 and March 31, 2024.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 97.15 | 79.70 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 69.07 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 15.99 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹169.54 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 63.20 | 35.84 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 25.07 | 38.46 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 1.76 | 1.50 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹13.51 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 48.02 | 27.38 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Fractal Industries IPO Retail Individual Investors (RII) are offered 7,54,800 shares while in Goldline Pharmaceutical IPO retail investors are offered 7,54,800 shares. Qualified Institutional Buyers (QIB) are offered 4,30,800 shares in Fractal Industries IPO and 0 shares in Goldline Pharmaceutical IPO.
| Fractal Industries IPO | Goldline Pharmaceutical IPO | |
|---|---|---|
| Anchor Investor Reservation | 6,45,000 shares | 0 shares |
| Market Maker Reservation | 1,14,000 shares | 0 shares |
| QIB | 4,30,800 shares | 0 shares |
| NII | 3,24,000 shares | 0 shares |
| RII | 7,54,800 shares | 0 shares |
| Employee | 0 shares | 0 shares |
| Others | ||
| Total | 21,54,600 shares | 0 shares |
Fractal Industries IPO subscribed 3.81x in total, whereas Goldline Pharmaceutical IPO subscribed .
| Fractal Industries IPO | Goldline Pharmaceutical IPO | |
|---|---|---|
| QIB (times) | 5.95x | |
| NII (times) | 7.91x | |
| Big NII (times) | 9.45x | |
| Small NII (times) | 4.85x | |
| RII (times) | 4.09x | |
| Employee (times) | ||
| Other (times) | ||
| Total (times) | 3.81x |
